Hemagglutinating virus of Japan‐envelope containing programmed cell death‐ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma

Sugii, Narushi; Matsuda, Masahide; Okumura, Genki; Shibuya, Akira; Ishikawa, Eiichi; Kaneda, Yasufumi; Matsumura, Akira

doi:10.1111/cas.14721

Cited by 9 publications

(5 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Presentation of tumor antigens by PD-L1-negative DCs to PD-1-silenced T lymphocytes led to the induction of potent cellular responses [116]. Several additional reports have confirmed that the use of siRNA silencing immune checkpoints are a promising tool for a new generation of therapeutic cancer vaccines [117][118][119].…”

Section: Small Non-coding Rnasmentioning

confidence: 96%

Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches

et al. 2022

View full text Add to dashboard Cite

In recent years, the use of immune checkpoint inhibitors (ICIs) in combination with approved or experimental vaccines has proven to be a promising approach to improve vaccine immunogenicity and efficacy. This strategy seeks to overcome the immunosuppressive mechanisms associated with the vaccine response, thereby achieving increased immunogenicity and efficacy. Most of the information on the use of ICIs combined with vaccines derives from studies on certain anti-tumor vaccines combined with monoclonal antibodies (mAbs) against either cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed death-ligand 1 (PD-L1). However, over the past few years, emerging strategies to use new-generation ICIs as molecular adjuvants are paving the way for future advances in vaccine research. Here, we review the current state and future directions of the use of ICIs in experimental and clinical settings, including mAbs and alternative new approaches using antisense oligonucleotides (ASOs), small non-coding RNAs, aptamers, peptides, and other small molecules for improving vaccine efficacy. The scope of this review mainly includes the use of ICIs in therapeutic antitumor vaccines, although recent research on anti-infective vaccines will also be addressed.

show abstract

Section: Small Non-coding Rnasmentioning

confidence: 96%

Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The administration of resveratrol and IL-2 in humans and mice increased NK cell activity in the blood and effectively inhibited tumor growth and metastasis in mice 76 . Using hemagglutinating virus of Japan-envelope (HVJ-E) a non-replicating virus-derived vector, it was possible to deliver siRNA that target PD-L1 expression 77 . HVJ-E provoked a robust anti-tumoral immunity by activating NK cells and CD8 + T lymphocytes 77 .…”

Section: Preclinical Advancements In Nk Cell Therapymentioning

confidence: 99%

“…Using hemagglutinating virus of Japan-envelope (HVJ-E) a non-replicating virus-derived vector, it was possible to deliver siRNA that target PD-L1 expression 77 . HVJ-E provoked a robust anti-tumoral immunity by activating NK cells and CD8 + T lymphocytes 77 .…”

Section: Preclinical Advancements In Nk Cell Therapymentioning

confidence: 99%

Advances in NK cell therapy for brain tumors

et al. 2023

View full text Add to dashboard Cite

Despite advances in treatment regimens that comprise surgery, chemotherapy, and radiation, outcome of many brain tumors remains dismal, more so when they recur. The proximity of brain tumors to delicate neural structures often precludes complete surgical resection. Toxicity and long-term side effects of systemic therapy remain a concern. Novel therapies are warranted. The field of NK cell-based cancer therapy has grown exponentially and currently constitutes a major area of immunotherapy innovation. This provides a new avenue for the treatment of cancerous lesions in the brain. In this review, we explore the mechanisms by which the brain tumor microenvironment suppresses NK cell mediated tumor control, and the methods being used to create NK cell products that subvert immune suppression. We discuss the pre-clinical studies evaluating NK cell-based immunotherapies that target several neuro-malignancies and highlight advances in molecular imaging of NK cells that allow monitoring of NK cell-based therapeutics. We review current and ongoing NK cell based clinical trials in neuro-oncology.

show abstract

“…And it provokes robust antitumoral immunity by activating natural killer cells and cytotoxic T lymphocytes and suppressing regulatory T lymphocytes. Thus, HVJ-E may be a new treatment option for GBM patients (Sugii et al, 2021).…”

Section: Zhou Et Al (2021)mentioning

confidence: 99%

Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery

Teng

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Gliomas are central nervous system tumors originating from glial cells, whose incidence and mortality rise in coming years. The current treatment of gliomas is surgery combined with chemotherapy or radiotherapy. However, developing therapeutic resistance is one of the significant challenges. Recent research suggested that small interfering RNA (siRNA) has excellent potential as a therapeutic to silence genes that are significantly involved in the manipulation of gliomas’ malignant phenotypes, including proliferation, invasion, metastasis, therapy resistance, and immune escape. However, it is challenging to deliver the naked siRNA to the action site in the cells of target tissues. Therefore, it is urgent to develop delivery strategies to transport siRNA to achieve the optimal silencing effect of the target gene. However, there is no systematic discussion about siRNAs’ clinical potential and delivery strategies in gliomas. This review mainly discusses siRNAs’ delivery strategies, especially nanotechnology-based delivery systems, as a potential glioma therapy. Moreover, we envisage the future orientation and challenges in translating these findings into clinical applications.

show abstract

Hemagglutinating virus of Japan‐envelope containing programmed cell death‐ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Cited by 9 publications

References 45 publications

Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches

Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches

Advances in NK cell therapy for brain tumors

Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery

Contact Info

Product

Resources

About